Trial document




drksid header

  DRKS00000390

Trial Description

start of 1:1-Block title

Title

Prevention of abdominal wound infection:
PROUD-Trial
A randomized controlled trial

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

PROUD-Trial

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

Wound infection remain one of the most important comlications after abdominal surgery.
This is an interventional trial to investigate the rates of wound infection within 30 days after midline incision for abdominal surgery using two different materials for abdominal closure:
1. continuous closure using a slowly absorbable material, wich is coated with Triclosan (IRGACARE® MP).
2. continuous closure using a slowly absorbable material, wich is not coated.
Patients with elective midline laparotomy for any reason (except for emergency surgery).
Rates of wound infection are assumes to be the same in both groups.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

To evaluate possible differences in the frequency of wound infections and wound dehiscence within one month after index operation using two different suture materials (PDS vs. PDS+) for continuous abdominal fascial closure after elective midline laparatomy.

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00000390
  •   2010/04/27
  •   [---]*
  •   yes
  •   Approved
  •   S-064/2010, Ethik-Kommission I der Medizinischen Fakultät Heidelberg
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   U1111-1114-6522 
  •   01/2010  (KSC Trial Number)
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   elective midline laparotomy
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   The abdomen will be closed by a continuous, all-layer suture using two loops of slowly absorbable monofilament suture =PDS II plus (coated with triclosan).
  •   The abdomen will be closed by a continuous, all-layer suture using two loops of slowly absorbable monofilament suture =PDS II
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Interventional
  •   [---]*
  •   Randomized controlled trial
  •   Blinded
  •   patient/subject, investigator/therapist, assessor
  •   Active control (effective treament of control group)
  •   Treatment
  •   Parallel
  •   N/A
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

Wound infection (deep and superficial according to CDC definition) within 30 days after surgery

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

Duration of surgery /
Length of incision /
Frequency of wound dehiscence (with or without evisceration) /
Frequency of re-operation due to wound dehiscence /
Postoperative intensive care unit stay /
Postoperative hospital stay /
30 day mortality /
Quality of life (QoL)

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • [---]*
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   Actual
  •   2010/04/07
  •   1200
  •   Multicenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   100   Years
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

age >= 18 years/

Patients undergoing elective midline laparatomy /

Informed consent

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

Participation in another intervention-trial with interference of intervention and / or outcome of this study /

Impaired mental state or language problems

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Universitätsklinik Heidelberg
    • Im Neuenheimer Feld 672
    • 69120  Heidelberg
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Chirurgische Universitätsklinik Heidelberg Studienzentrum der Deutschen Gesellschaft für Chirurgie-SDGC
    • Ms.  Colette  Dörr-Harim 
    • Im Neuenheimer Feld 110
    • 69120  Heidelberg
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Chirurgische Universitätsklinik Heidelberg Studienzentrum der Deutschen Gesellschaft für Chirurgie-SDGC
    • Ms.  Colette   Dörr-Harim 
    • Im Neuenheimer Feld 110
    • 69120  Heidelberg
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • ETHICON UK, a division of JOHNSON & JOHNSON MEDICAL LIMITED Kirkton Campus Scotland
    • P.O. Box 1988
    • EH54 0AB  Livingston EH54 0AB
    • United Kingdom
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting complete, follow-up complete
  •   2012/11/18
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.